<div id="readability-page-1"><div><ul> <li>Catalyst Pharmaceuticals, ticker NasdaqCM:CPRX, has agreed to be acquired by Angelini Pharma in a definitive all cash transaction.</li> <li>The company has settled all pending Firdapse patent litigation, granting generic licenses that run through 2035.</li> <li>The deal marks an exit for current public shareholders and is set to reshape how Catalyst Pharmaceuticals operates within the rare disease drug market.</li> </ul> <p>Catalyst Pharmaceuticals focuses on treatments for rare neurological conditions, with Firdapse as a key product. The all cash acquisition by Angelini Pharma and the resolution of Firdapse patent disputes arrive at a time when rare disease drugs remain a core area of interest for many large healthcare groups. For you as a shareholder or sector watcher, these moves change the story around NasdaqCM:CPRX from independent growth to integration within a larger pharmaceutical group.</p> <p>The long term generic licensing framework on Firdapse through 2035 provides a clearer view of how competition around this product may develop. Investors following NasdaqCM:CPRX may now pay closer attention to the transaction terms, the expected timeline to closing, and how the combined business could position its rare disease portfolio after the deal completes.</p> <p>Stay updated on the most important news stories for Catalyst Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Catalyst Pharmaceuticals.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c52b3e44-8ab3-4c21-8642-d3074664ed08/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c52b3e44-8ab3-4c21-8642-d3074664ed08/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE3"/><figcaption>NasdaqCM:CPRX Earnings &amp; Revenue Growth as at May 2026</figcaption></figure> <p>3 things going right for Catalyst Pharmaceuticals that this headline doesn't cover.</p> <p>The Angelini Pharma all cash deal effectively gives public shareholders a defined exit price while placing Catalyst’s rare disease portfolio inside a larger European headquartered pharmaceutical group. For you, the near term focus shifts from quarterly moves in Firdapse, Agamree or Fycompa to the likelihood and timing of deal completion, because the company is expected to be delisted once the transaction closes. The settlement of all Firdapse patent disputes, with generic entry in the United States not expected before January 2035 for Hetero under the agreement, removes a key legal overhang that previously sat alongside revenue concentration in one flagship drug. Combined with Q1 2026 revenue of US$149.39 million and net income of US$63.73 million, the business is being acquired while it is reporting profitable operations. For Angelini Pharma, the portfolio adds scale in rare neurological diseases and expands reach in the US market, where groups such as Biogen, UCB and Jazz Pharmaceuticals are also active. For current shareholders, the set of conditions that still needs to be cleared includes stockholder approval, regulatory and antitrust sign offs, and the practical execution of the financing package.</p> <h3>How This Fits Into The Catalyst Pharmaceuticals Narrative</h3> <ul> <li>The acquisition and the Firdapse litigation settlement are consistent with a narrative that emphasises durable margins, cash generation and business development as a way to grow a rare disease portfolio.</li> <li>The move to sell the company may challenge expectations that Catalyst would keep using its balance sheet and cash flows to pursue independent product launches and acquisitions over many years.</li> <li>The definitive US$3.9b all cash deal and the agreed generic licences through 2035 are not fully reflected in earlier narrative discussions that centred on open ended patent risk and the timing of possible generic competition.</li> </ul> <p>Knowing what a company is worth starts with understanding its story.                          Check out one of the top narratives in the Simply Wall St Community for Catalyst Pharmaceuticals to help decide what it's worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>⚠️ The deal may not close if stockholders do not approve it, if regulators raise concerns, or if financing and customary conditions are not satisfied. This could leave the stock trading without the support of a confirmed takeout price.</li> <li>⚠️ Even with Firdapse patent litigation settled and licences set through 2035 for current counterparties, Catalyst still carries product concentration risk if future therapies in similar indications reduce demand for its key drugs.</li> <li>🎁 The all cash consideration of US$31.5 per share provides clarity on the value Angelini Pharma is willing to pay for Catalyst’s current earnings profile and rare disease portfolio.</li> <li>🎁 Resolving all pending Firdapse patent litigation removes legal uncertainty around a core asset, which may simplify how you think about cash flows from that product through the agreed generic licence period.</li> </ul> <h3>What To Watch Going Forward</h3> <p>From here, it makes sense to watch progress against the stated closing timeline in the third quarter of 2026, including the stockholder vote date, regulatory filings and any commentary on antitrust review. Deal spreads relative to the US$31.5 per share offer price can also give you a market based read on perceived completion risk. On the operating side, quarterly updates on sales of Firdapse, Agamree and the broader portfolio remain relevant, because they influence how both parties view the business if any renegotiation or competing interest emerges. Finally, keep an eye on any disclosures about integration plans from Angelini Pharma, especially around how it intends to position Catalyst’s products against offerings from competitors such as Biogen, UCB and Jazz Pharmaceuticals in rare neurological and seizure related conditions.</p> <p>To ensure you're always in the loop on how the latest news impacts the investment narrative for Catalyst Pharmaceuticals, head to the                          community page for Catalyst Pharmaceuticals to never miss an update on the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

CPRX

<p>Catalyst Pharmaceuticals (NasdaqCM: CPRX) has agreed to an all-cash acquisition by Angelini Pharma, settling Firdapse patent litigation and granting generic licenses until 2035. This deal marks a shift for Catalyst from independent growth to integration within a larger pharmaceutical group, providing a defined exit for shareholders. The acquisition, valued at $3.9 billion, is expected to close in Q3 2026, pending stockholder and regulatory approvals. Investors should monitor the transaction's progress and the performance of Catalyst's product portfolio.</p>

Angelini Buyout And Firdapse Settlement Reframe Catalyst Pharmaceuticals Story